Information Provided By:
Fly News Breaks for April 15, 2016
VRX
Apr 15, 2016 | 14:55 EDT
Wells Fargo analyst David Maris says his review of IMS Heath prescription data indicate that total and new prescriptions of Xifaxan, which is Valeant's largest product, may have plateaued in the last six months. Slowing growth and the potential for generics may make a divestiture of Xifaxan challenging, said Maris, who keeps an Underperform rating on Valeant shares.
News For VRX From the Last 2 Days
There are no results for your query VRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.